A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention.

Trial Profile

A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Donepezil (Primary) ; Risperidone
  • Indications Agitation; Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms CALM-AD
  • Most Recent Events

    • 09 Sep 2009 Planned number of patients changed from 190 to 285 as reported by ISRCTN: Current Controlled Trials.
    • 04 Oct 2007 Results have been published in the New England Journal of Medicine 357: 1382-1392, No. 14.
    • 11 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top